To investigate the intraindividual pharmacokinetics of total (protein bound + unbound) and unbound lopinavir/ritonavir (LPV/RTV) and to assess whether the pediatric formulation (100mg/25mg) can overcome any pregnancy-associated changes
Objective: To evaluate the pharmacokinetics and HIV viral load response following initiation during ...
Pharmacokinetic boosting of antiretroviral (ARV) therapies with either ritonavir or cobicistat is us...
Introduction: During pregnancy, LPV/r is a common anchor drug employed to treat the mother's HIV-1 i...
To investigate the intraindividual pharmacokinetics of total (protein bound + unbound) and unbound l...
Lopinavir/ritonavir (LPV/r) based regimen is recommended during pregnancy to reduce the risk of HIV ...
ABSTRACT Lopinavir-ritonavir is frequently prescribed to HIV-1-infected women during pregnancy. Decr...
A lopinavir-ritonavir (LPV/r)-based regimen is recommended during pregnancy to reduce the risk of HI...
A lopinavir-ritonavir (LPV/r)-based regimen is recommended during pregnancy to reduce the risk of HI...
BACKGROUND: Physiological changes associated with pregnancy may alter antiretroviral plasma concentr...
BACKGROUND: Physiological changes associated with pregnancy may alter antiretroviral plasma concentr...
Lopinavir exposure was reduced during the third trimester in pregnant women receiving standard dosin...
Objectives: To assess the influence of body weight and missed doses on lopinavir pharmacokinetics wi...
OBJECTIVES: An observational, open-label study was performed to assess changes of lopinavir/ritonavi...
OBJECTIVES: To describe laboratory abnormalities among HIV-infected women and their infants with sta...
OBJECTIVES: To investigate whether Thai HIV-1-infected pregnant women require a dose increase of lop...
Objective: To evaluate the pharmacokinetics and HIV viral load response following initiation during ...
Pharmacokinetic boosting of antiretroviral (ARV) therapies with either ritonavir or cobicistat is us...
Introduction: During pregnancy, LPV/r is a common anchor drug employed to treat the mother's HIV-1 i...
To investigate the intraindividual pharmacokinetics of total (protein bound + unbound) and unbound l...
Lopinavir/ritonavir (LPV/r) based regimen is recommended during pregnancy to reduce the risk of HIV ...
ABSTRACT Lopinavir-ritonavir is frequently prescribed to HIV-1-infected women during pregnancy. Decr...
A lopinavir-ritonavir (LPV/r)-based regimen is recommended during pregnancy to reduce the risk of HI...
A lopinavir-ritonavir (LPV/r)-based regimen is recommended during pregnancy to reduce the risk of HI...
BACKGROUND: Physiological changes associated with pregnancy may alter antiretroviral plasma concentr...
BACKGROUND: Physiological changes associated with pregnancy may alter antiretroviral plasma concentr...
Lopinavir exposure was reduced during the third trimester in pregnant women receiving standard dosin...
Objectives: To assess the influence of body weight and missed doses on lopinavir pharmacokinetics wi...
OBJECTIVES: An observational, open-label study was performed to assess changes of lopinavir/ritonavi...
OBJECTIVES: To describe laboratory abnormalities among HIV-infected women and their infants with sta...
OBJECTIVES: To investigate whether Thai HIV-1-infected pregnant women require a dose increase of lop...
Objective: To evaluate the pharmacokinetics and HIV viral load response following initiation during ...
Pharmacokinetic boosting of antiretroviral (ARV) therapies with either ritonavir or cobicistat is us...
Introduction: During pregnancy, LPV/r is a common anchor drug employed to treat the mother's HIV-1 i...